Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Julphar
McKinsey
Cipla
Boehringer Ingelheim
Harvard Business School

Generated: May 25, 2019

DrugPatentWatch Database Preview

Details for Patent: 10,093,654

« Back to Dashboard

Which drugs does patent 10,093,654 protect, and when does it expire?

Patent 10,093,654 protects IDHIFA and is included in one NDA.

This patent has twenty-three patent family members in eighteen countries.

Summary for Patent: 10,093,654
Title:Therapeutically active compounds and their methods of use
Abstract: Provided are compounds useful for treating cancer and methods of treating cancer, comprising administering to a subject in need thereof a compound described herein.
Inventor(s): Agresta; Samuel V. (Lexington, MA), Gu; Chong-Hui (Waban, MA), Schenkein; David (Boston, MA), Yang; Hua (Acton, MA), Guo; Liting (Suzhou, CN), Tang; Zhen (Suzhou, CN), Wang; Jianming (Suzhou, CN), Zhang; Yanfeng (Suzhou, CN), Zhou; Yan (Suzhou, CN)
Assignee: Agios Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:15/649,551
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 10,093,654
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 10,093,654

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Celgene Corp IDHIFA enasidenib mesylate TABLET;ORAL 209606-001 Aug 1, 2017 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION ➤ Try a Free Trial
Celgene Corp IDHIFA enasidenib mesylate TABLET;ORAL 209606-002 Aug 1, 2017 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 10,093,654

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
PCT/CN2013/081170Aug 9, 2013

International Family Members for US Patent 10,093,654

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 097237 ➤ Try a Free Trial
Australia 2014295938 ➤ Try a Free Trial
Australia 2018247242 ➤ Try a Free Trial
Brazil 112016002287 ➤ Try a Free Trial
Canada 2919382 ➤ Try a Free Trial
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Baxter
Farmers Insurance
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.